source
- Spyre shares plunge as rheumatoid arthritis trial of SPY072 falls short of internal targetSpyre Therapeutics reported that its antibody SPY072 did not meet the company’s internal criteria in a mid‑stage rheumatoid arthritis trial, despite showing some activity. The placebo‑controlled s…
- Hansoh says China’s biopharma is shifting from follower to frontrunner, now behind 30% of investigational drugsHansoh Pharmaceutical used its first‑half earnings release to claim that China’s innovative biopharma sector is moving from a follower role to a frontrunner position. The company highlighted that…